Reported 3 days ago
CRISPR Therapeutics, despite a 24% stock drop since mid-2022, could offer significant returns for patient investors. The company recently received approval for its first therapy, Casgevy, aimed at treating sickle cell disease and beta-thalassemia. While Casgevy's high costs and complex manufacturing pose challenges, its approval serves as proof of the viability of CRISPR's approach. With promising clinical trials for other therapies like CTX310, the company's success in future regulatory milestones could lead to soaring stock prices and broader acceptance of gene-editing medicines.
Source: YAHOO